Tüdőrák: vizsgálatok itt: Hollandia
141 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Alkmaar, Ede Gld, Leidschendam, Veldhoven, Zwolle
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Alkmaar, Ede Gld, Leidschendam, Veldhoven
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 1/2. fázisNot yet taking people in HollandiaA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Amsterdam, Groningen, Leiden
- Életkor
- 18 év and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01 - 3. fázisTaking peopleA phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
- Where
- Groningen, Nijmegen, Rotterdam
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to join2023-509340-10-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Amersfoort, Nijmegen, 'S-Hertogenbosch, Tilburg
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Amsterdam, Heerlen, Leeuwarden, Maastricht, Utrecht
- Életkor
- 18 év and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - 1. fázisTaking peopleWhole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 20
- Run by
- The Netherlands Cancer Institute
See details and how to joinNCT07436858 · EU 2026-525568-17-00 - 3. fázisTaking peopleA Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
- Where
- Amersfoort, Breda, Groningen, Harderwijk, Hilversum, Zwolle
- Életkor
- 18 év and over
- People
- 263 worldwide
- Run by
- Zai Lab (US) LLC
See details and how to join2025-522818-23-00 - 1/2. fázisTaking peopleStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Where
- Amsterdam, Leiden, Utrecht
- Életkor
- 18 év and over
- People
- 616 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00 - No phaseNot yet taking people in HollandiaPRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
- Where
- Groningen
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253 - 3. fázisTaking peopleA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Where
- Breda, Hilversum
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146 - 1/2. fázisNot yet taking people in HollandiaPET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER
- Where
- Nijmegen
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Radboud universitair medisch centrum Stichting
See details and how to join2025-524791-30-00 - 1. fázisTaking peopleA Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 12
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05963867 - 3. fázisFelfüggesztveSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Where
- Heerlen, 'S-Hertogenbosch, Tilburg
- Életkor
- 18 év and over
- People
- 621 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00 - 2/3. fázisNot yet taking people in HollandiaIZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Where
- Amsterdam, Harderwijk
- Életkor
- 18 év and over
- People
- 173 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Amsterdam
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 3. fázisFelfüggesztveA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Harderwijk, Leiden, Nijmegen
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - 1. fázisTaking peopleStudy of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
- Where
- Amsterdam, Groningen, Leiden, Utrecht
- Életkor
- 18 év and over
- People
- 330 worldwide
- Run by
- Revolution Medicines Inc.
See details and how to join2023-509571-16-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Amersfoort, Amsterdam, Arnhem, Breda, Harderwijk, Leidschendam, Zwolle
- Életkor
- 18 év and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Amsterdam, Leiden, Nijmegen, Rotterdam, Utrecht
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 2. fázisNot yet taking people in HollandiaRADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
- Where
- Amsterdam, Leiden
- Életkor
- 18 év and over
- People
- 30
- Run by
- The Netherlands Cancer Institute
See details and how to joinNCT07808138 · EU 2025-524305-32-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Amsterdam, Nijmegen, Utrecht
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - 1/2. fázisTaking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Amsterdam, Groningen
- Életkor
- 12 év and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - 1/2. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Where
- Amsterdam, Leiden
- Életkor
- 18 év and over
- People
- 416 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06618287 - 1. fázisTaking peopleA study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
- Where
- Amsterdam, Groningen, Leiden, Utrecht
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Revolution Medicines Inc.
See details and how to join2023-509572-42-00